1
|
Yee YC, Mori T, Ito S, Taguchi T, Katayama Y. Impact of hydrophobic modification on biocompatibility of Alaska pollock gelatin microparticles. ANAL SCI 2024:10.1007/s44211-024-00643-2. [PMID: 39120821 DOI: 10.1007/s44211-024-00643-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2024] [Accepted: 07/28/2024] [Indexed: 08/10/2024]
Abstract
This study investigates the impact of hydrophobic modification on the immunogenicity, cytotoxicity, and inflammatory response of Alaska pollock gelatin (ApGltn) microparticles (MPs). Gelatin, known for its inherent biocompatibility, was modified with decyl group (C10) to explore potential alterations in its interaction with the immune system. Immunogenicity was evaluated through the measurement of material-specific IgM and IgG responses, indicating no significant increase post-modification. Cytotoxicity against Caco-2 cell lines and NF-κB-mediated LPS-induced inflammation were also assessed, revealing no exacerbation by the modified MPs. Furthermore, C10 modification with different types of linkage such as secondary amine and amide structure did not influence immune reactivity. These findings suggest that C10 modification maintains the non-immunogenicity and biocompatibility of gelatin MPs, supporting their potential use in biomedical applications.
Collapse
Affiliation(s)
- Ying Chuin Yee
- Department of Applied Chemistry, Graduate School of Engineering, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka, 819-0395, Japan
| | - Takeshi Mori
- Department of Applied Chemistry, Graduate School of Engineering, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka, 819-0395, Japan.
- Center for Future Chemistry, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka, 819-0395, Japan.
| | - Shima Ito
- Degree Programs in Pure and Applied Sciences, Graduate School of Science and Technology, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8577, Japan
- Biomaterials Field, Research Center for Macromolecules and Biomaterials, National Institute for Materials Science, 1-1 Namiki, Tsukuba, Ibaraki, 305-0044, Japan
| | - Tetsushi Taguchi
- Degree Programs in Pure and Applied Sciences, Graduate School of Science and Technology, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8577, Japan.
- Biomaterials Field, Research Center for Macromolecules and Biomaterials, National Institute for Materials Science, 1-1 Namiki, Tsukuba, Ibaraki, 305-0044, Japan.
| | - Yoshiki Katayama
- Department of Applied Chemistry, Graduate School of Engineering, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka, 819-0395, Japan.
- Center for Future Chemistry, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka, 819-0395, Japan.
- Center for Molecular Systems, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka, 819-0395, Japan.
- Centre for Advanced Medicine Open Innovation, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
- Department of Biomedical Engineering, Chung Yuan Christian University, 200 Chung Pei Rd., Chung Li, 32023, Taiwan, ROC.
| |
Collapse
|
2
|
Gong W, Pan C, Cheng P, Wang J, Zhao G, Wu X. Peptide-Based Vaccines for Tuberculosis. Front Immunol 2022; 13:830497. [PMID: 35173740 PMCID: PMC8841753 DOI: 10.3389/fimmu.2022.830497] [Citation(s) in RCA: 34] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2021] [Accepted: 01/10/2022] [Indexed: 12/12/2022] Open
Abstract
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis. As a result of the coronavirus disease 2019 (COVID-19) pandemic, the global TB mortality rate in 2020 is rising, making TB prevention and control more challenging. Vaccination has been considered the best approach to reduce the TB burden. Unfortunately, BCG, the only TB vaccine currently approved for use, offers some protection against childhood TB but is less effective in adults. Therefore, it is urgent to develop new TB vaccines that are more effective than BCG. Accumulating data indicated that peptides or epitopes play essential roles in bridging innate and adaptive immunity and triggering adaptive immunity. Furthermore, innovations in bioinformatics, immunoinformatics, synthetic technologies, new materials, and transgenic animal models have put wings on the research of peptide-based vaccines for TB. Hence, this review seeks to give an overview of current tools that can be used to design a peptide-based vaccine, the research status of peptide-based vaccines for TB, protein-based bacterial vaccine delivery systems, and animal models for the peptide-based vaccines. These explorations will provide approaches and strategies for developing safer and more effective peptide-based vaccines and contribute to achieving the WHO's End TB Strategy.
Collapse
Affiliation(s)
- Wenping Gong
- Tuberculosis Prevention and Control Key Laboratory/Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Senior Department of Tuberculosis, The 8th Medical Center of PLA General Hospital, Beijing, China
| | - Chao Pan
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Biotechnology, Beijing, China
| | - Peng Cheng
- Tuberculosis Prevention and Control Key Laboratory/Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Senior Department of Tuberculosis, The 8th Medical Center of PLA General Hospital, Beijing, China
- Hebei North University, Zhangjiakou City, China
| | - Jie Wang
- Tuberculosis Prevention and Control Key Laboratory/Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Senior Department of Tuberculosis, The 8th Medical Center of PLA General Hospital, Beijing, China
| | - Guangyu Zhao
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
| | - Xueqiong Wu
- Tuberculosis Prevention and Control Key Laboratory/Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Senior Department of Tuberculosis, The 8th Medical Center of PLA General Hospital, Beijing, China
| |
Collapse
|
3
|
Abstract
![]()
The development of
lipopeptides (lipidated peptides) for vaccines
is discussed, including their role as antigens and/or adjuvants. Distinct
classes of lipopeptide architectures are covered including simple
linear and ligated constructs and lipid core peptides. The design,
synthesis, and immunological responses of the important class of glycerol-based
Toll-like receptor agonist lipopeptides such as Pam3CSK4, which contains three palmitoyl chains and a CSK4 hexapeptide sequence, and many derivatives of this model immunogenic
compound are also reviewed. Self-assembled lipopeptide structures
including spherical and worm-like micelles that have been shown to
act as vaccine agents are also described. The work discussed includes
examples of lipopeptides developed with model antigens, as well as
for immunotherapies to treat many infectious diseases including malaria,
influenza, hepatitis, COVID-19, and many others, as well as cancer
immunotherapies. Some of these have proceeded to clinical development.
The research discussed highlights the huge potential of, and diversity
of roles for, lipopeptides in contemporary and future vaccine development.
Collapse
Affiliation(s)
- Ian W Hamley
- Department of Chemistry, University of Reading, Whiteknights, Reading RG6 6AD, U.K
| |
Collapse
|
4
|
Root-Bernstein R. Synergistic Activation of Toll-Like and NOD Receptors by Complementary Antigens as Facilitators of Autoimmune Disease: Review, Model and Novel Predictions. Int J Mol Sci 2020; 21:ijms21134645. [PMID: 32629865 PMCID: PMC7369971 DOI: 10.3390/ijms21134645] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2020] [Revised: 06/26/2020] [Accepted: 06/27/2020] [Indexed: 12/29/2022] Open
Abstract
Persistent activation of toll-like receptors (TLR) and nucleotide-binding oligomerization domain-containing proteins (NOD) in the innate immune system is one necessary driver of autoimmune disease (AD), but its mechanism remains obscure. This study compares and contrasts TLR and NOD activation profiles for four AD (autoimmune myocarditis, myasthenia gravis, multiple sclerosis and rheumatoid arthritis) and their animal models. The failure of current AD theories to explain the disparate TLR/NOD profiles in AD is reviewed and a novel model is presented that explains innate immune support of persistent chronic inflammation in terms of unique combinations of complementary AD-specific antigens stimulating synergistic TLRs and/or NODs. The potential explanatory power of the model is explored through testable, novel predictions concerning TLR- and NOD-related AD animal models and therapies.
Collapse
|
5
|
Azuar A, Jin W, Mukaida S, Hussein WM, Toth I, Skwarczynski M. Recent Advances in the Development of Peptide Vaccines and Their Delivery Systems Against Group A Streptococcus. Vaccines (Basel) 2019; 7:E58. [PMID: 31266253 PMCID: PMC6789462 DOI: 10.3390/vaccines7030058] [Citation(s) in RCA: 46] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2019] [Revised: 06/21/2019] [Accepted: 06/25/2019] [Indexed: 02/07/2023] Open
Abstract
Group A Streptococcus (GAS) infection can cause a variety of diseases in humans, ranging from common sore throats and skin infections, to more invasive diseases and life-threatening post-infectious diseases, such as rheumatic fever and rheumatic heart disease. Although research has been ongoing since 1923, vaccines against GAS are still not available to the public. Traditional approaches taken to develop vaccines for GAS failed due to poor efficacy and safety. Fortunately, headway has been made and modern subunit vaccines that administer minimal bacterial components provide an opportunity to finally overcome previous hurdles in GAS vaccine development. This review details the major antigens and strategies used for GAS vaccine development. The combination of antigen selection, peptide epitope modification and delivery systems have resulted in the discovery of promising peptide vaccines against GAS; these are currently in preclinical and clinical studies.
Collapse
Affiliation(s)
- Armira Azuar
- School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, QLD 4072, Australia
| | - Wanli Jin
- School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, QLD 4072, Australia
| | - Saori Mukaida
- School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, QLD 4072, Australia
| | - Waleed M Hussein
- School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, QLD 4072, Australia
- Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Helwan University, Helwan, Cairo 11795, Egypt
| | - Istvan Toth
- School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, QLD 4072, Australia
- School of Pharmacy, Woolloongabba, The University of Queensland, QLD 4072, Australia
- Institute of Molecular Bioscience, The University of Queensland, St. Lucia, QLD 4072, Australia
| | - Mariusz Skwarczynski
- School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, QLD 4072, Australia.
| |
Collapse
|
6
|
Fagan V, Hussein WM, Su M, Giddam AK, Batzloff MR, Good MF, Toth I, Simerska P. Synthesis, Characterization and Immunological Evaluation of Self‐Adjuvanting Group A Streptococcal Vaccine Candidates Bearing Various Lipidic Adjuvanting Moieties. Chembiochem 2017; 18:545-553. [DOI: 10.1002/cbic.201600639] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2016] [Indexed: 11/10/2022]
Affiliation(s)
- Vincent Fagan
- School of Chemistry and Molecular Biosciences The University of Queensland Cooper Road St. Lucia QLD 4072 Australia
| | - Waleed M. Hussein
- School of Chemistry and Molecular Biosciences The University of Queensland Cooper Road St. Lucia QLD 4072 Australia
| | - Mei Su
- School of Chemistry and Molecular Biosciences The University of Queensland Cooper Road St. Lucia QLD 4072 Australia
| | - Ashwini K. Giddam
- School of Chemistry and Molecular Biosciences The University of Queensland Cooper Road St. Lucia QLD 4072 Australia
| | | | - Michael F. Good
- Institute for Glycomics Griffith University Gold Coast 4215 Australia
| | - Istvan Toth
- School of Chemistry and Molecular Biosciences The University of Queensland Cooper Road St. Lucia QLD 4072 Australia
- School of Pharmacy Pharmacy Australia Centre of Excellence The University of Queensland Cornwall Street Woolloongabba QLD 4072 Australia
- Institute for Molecular Bioscience The University of Queensland St. Lucia QLD 4072 Australia
| | - Pavla Simerska
- School of Chemistry and Molecular Biosciences The University of Queensland Cooper Road St. Lucia QLD 4072 Australia
| |
Collapse
|
7
|
Status of research and development of vaccines for Streptococcus pyogenes. Vaccine 2016; 34:2953-2958. [DOI: 10.1016/j.vaccine.2016.03.073] [Citation(s) in RCA: 96] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2015] [Accepted: 03/09/2016] [Indexed: 11/23/2022]
|
8
|
Apte SH, Stephenson RJ, Simerska P, Groves PL, Aljohani S, Eskandari S, Toth I, Doolan DL. Systematic evaluation of self-adjuvanting lipopeptide nano-vaccine platforms for the induction of potent CD8(+) T-cell responses. Nanomedicine (Lond) 2015; 11:137-52. [PMID: 26653407 DOI: 10.2217/nnm.15.184] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
AIM Systematically evaluate lipid core peptide vaccine delivery platforms to identify core features promoting strong CD8(+) T-cell responses. MATERIALS & METHODS Three different self-adjuvanting lipid core peptide nanovaccines each comprising four copies of the dominant ovalbumin CD8(+) T-cell epitope and varying in the utilization of a polylysine or glucose core with 2-amino-hexadecanoic acid (C16) or 2-amino-dodecanoic acid (C12) lipids were synthesized. Vaccines were tested for ability to induce CD8(+) T-cell responses and inhibit tumor growth in vivo. RESULTS The construct utilizing C12 lipids and polylysine core induced very robust effector T cells shown to have in vivo effector capability as demonstrated by in vivo cytotoxicity and ability to inhibit tumor growth as well as modulation of dendritic cell activation. CONCLUSION The C12 polylysine platform was an effective configuration for induction of potent CD8(+) T-cell responses.
Collapse
Affiliation(s)
- Simon H Apte
- Infectious Diseases Programme, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia
| | - Rachel J Stephenson
- School of Chemistry & Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia
| | - Pavla Simerska
- School of Chemistry & Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia
| | - Penny L Groves
- Infectious Diseases Programme, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia
| | - Salwa Aljohani
- School of Chemistry & Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia
| | - Sharareh Eskandari
- School of Chemistry & Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia
| | - Istvan Toth
- School of Chemistry & Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia.,School of Pharmacy, The University of Queensland, Woolloongabba, QLD 4012, Australia.,Institute for Molecular Bioscience, The University of Queensland, St Lucia, QLD 4072, Australia
| | - Denise L Doolan
- Infectious Diseases Programme, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia
| |
Collapse
|
9
|
Dougall AM, Skwarczynski M, Khoshnejad M, Chandrudu S, Daly NL, Toth I, Loukas A. Lipid core peptide targeting the cathepsin D hemoglobinase of Schistosoma mansoni as a component of a schistosomiasis vaccine. Hum Vaccin Immunother 2013; 10:399-409. [PMID: 24231271 DOI: 10.4161/hv.27057] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
The self-adjuvanting lipid core peptide (LCP) system offers a safe alternative vaccine delivery strategy, eliminating the need for additional adjuvants such as CpG Alum. In this study, we adopted the LCP as a scaffold for an epitope located on the surface of the cathepsin D hemoglobinase (Sm-CatD) of the human blood fluke Schistosoma mansoni. Sm-CatD plays a pivotal role in digestion of the fluke's bloodmeal and has been shown to be efficacious as a subunit vaccine in a murine model of human schistosomiasis. Using molecular modeling we showed that S. mansoni cathepsin D possesses a predicted surface exposed α-helix (A₂₆₃K) that corresponds to an immunodominant helix and target of enzyme-neutralizing antibodies against Necator americanus APR-1 (Na-APR-1), the orthologous protease and vaccine antigen from blood-feeding hookworms. The A₂₆₃K epitope was engineered as two peptide variants, one of which was flanked at both termini with a coil maintaining sequence, thereby promoting the helical characteristics of the native A₂₆₃K epitope. Some of the peptides were fused to a self-adjuvanting lipid core scaffold to generate LCPs. Mice were vaccinated with unadjuvanted peptides, peptides formulated with Freund's adjuvants, or LCPs. Antibodies generated to LCPs recognized native Sm-CatD within a soluble adult schistosome extract, and almost completely abolished its enzymatic activity in vitro. Using immunohistochemistry we showed that anti-LCP antibodies bound to the native Sm-CatD protein in the esophagus and anterior regions of the gastrodermis of adult flukes. Vaccines offer an alternative control strategy in the fight against schistosomiasis, and further development of LCPs containing multiple epitopes from this and other vaccine antigens should become a research priority.
Collapse
Affiliation(s)
- Annette M Dougall
- Australian Institute of Tropical Health and Medicine; Centre for Biodiscovery and Molecular Development of Therapeutics; James Cook University; Cairns, QLD Australia
| | - Mariusz Skwarczynski
- Australian Institute of Tropical Health and Medicine; Centre for Biodiscovery and Molecular Development of Therapeutics; James Cook University; Cairns, QLD Australia; The University of Queensland; School of Chemistry and Molecular Biosciences; St. Lucia; QLD Australia; The University of Queensland; School of Pharmacy; Wooloongabba, QLD Australia
| | - Makan Khoshnejad
- The University of Queensland; School of Chemistry and Molecular Biosciences; St. Lucia; QLD Australia
| | - Saranya Chandrudu
- The University of Queensland; School of Chemistry and Molecular Biosciences; St. Lucia; QLD Australia
| | - Norelle L Daly
- Australian Institute of Tropical Health and Medicine; Centre for Biodiscovery and Molecular Development of Therapeutics; James Cook University; Cairns, QLD Australia
| | - Istvan Toth
- Australian Institute of Tropical Health and Medicine; Centre for Biodiscovery and Molecular Development of Therapeutics; James Cook University; Cairns, QLD Australia; The University of Queensland; School of Chemistry and Molecular Biosciences; St. Lucia; QLD Australia; The University of Queensland; School of Pharmacy; Wooloongabba, QLD Australia
| | - Alex Loukas
- Australian Institute of Tropical Health and Medicine; Centre for Biodiscovery and Molecular Development of Therapeutics; James Cook University; Cairns, QLD Australia
| |
Collapse
|
10
|
Zaman M, Toth I. Immunostimulation by synthetic lipopeptide-based vaccine candidates: structure-activity relationships. Front Immunol 2013; 4:318. [PMID: 24130558 PMCID: PMC3793171 DOI: 10.3389/fimmu.2013.00318] [Citation(s) in RCA: 65] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2013] [Accepted: 09/19/2013] [Indexed: 12/23/2022] Open
Abstract
Peptide-based vaccines offer several advantages over conventional whole organism or protein approaches by offering improved purity and specificity in inducing immune response. However, peptides alone are generally non-immunogenic. Concerns remain about the toxicity of adjuvants which are critical for immunogenicity of synthetic peptides. The use of lipopeptides in peptide vaccines is currently under intensive investigation because potent immune responses can be generated without the use of adjuvant (thus are self-adjuvanting). Several lipopeptides derived from microbial origin, and their synthetic versions or simpler fatty acid moieties impart this self-adjuvanting activity by signaling via Toll-like receptor 2 (TLR2). Engagement of this innate immune receptor on antigen-presenting cell leads to the initiation and development of potent immune responses. Therefore optimization of lipopeptides to enhance TLR2-mediated activation is a promising strategy for vaccine development. Considerable structure-activity relationships that determine TLR2 binding and consequent stimulation of innate immune responses have been investigated for a range of lipopeptides. In this mini review we address the development of lipopeptide vaccines, mechanism of TLR2 recognition, and immune activation. An overview is provided of the best studied lipopeptide vaccine systems.
Collapse
Affiliation(s)
- Mehfuz Zaman
- School of Chemistry and Molecular Biosciences, The University of Queensland , St Lucia, QLD , Australia
| | | |
Collapse
|
11
|
Galdiero S, Vitiello M, Finamore E, Mansi R, Galdiero M, Morelli G, Tesauro D. Activation of monocytic cells by immunostimulatory lipids conjugated to peptide antigens. MOLECULAR BIOSYSTEMS 2013; 8:3166-77. [PMID: 22710358 DOI: 10.1039/c2mb25064k] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Bacterial derived lipoproteins constitute potent macrophage activators in vivo and are effective stimuli, enhancing the immune response especially with respect to low or non-immunogenic compounds. In the present study we have prepared branched lipopeptide constructs in which different (B- and T-cell) epitopes of Herpes simplex virus type 1, derived from glycoproteins B (gB) and D (gD), are linked to a synthetic lipid core. The ability of the lipid core peptide (LCP) constructs (LCP-gB and LCP-gD) to induce cytokine expression and activate the mitogen-activated protein kinase cascade has been evaluated and compared with the behaviour of the isolated epitopes and the lipid core. In this respect, the use of LCP technology coupled with the use of three different gB or gD peptide epitopes in the same branched constructs could represent an interesting approach in order to obtain efficient delivery systems in the development of a synthetic multiepitopic vaccine for the prevention of viral infections.
Collapse
Affiliation(s)
- Stefania Galdiero
- Department of Biological Sciences, Division of Biostructures, Centro Interuniversitario di Ricerca sui Peptidi Bioattivi - University of Naples "Federico II", Istituto di Biostrutture e Bioimmagini - CNR, Via Mezzocannone 16, 80134, Naples, Italy
| | | | | | | | | | | | | |
Collapse
|
12
|
Sidiq T, Khajuria A, Shafi S, Ismail T, Sampath Kumar H, Kannappa Srinivas V, Krishna E, Kamal Johri R. Efficacy evaluation of two synthetic lysine lipidated tripeptides as vaccine adjuvants against HBsAg. Eur J Pharmacol 2013; 705:68-78. [PMID: 23474022 DOI: 10.1016/j.ejphar.2013.01.064] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2012] [Revised: 01/22/2013] [Accepted: 01/31/2013] [Indexed: 11/17/2022]
Abstract
In the present investigation, adjuvant potential of two novel lipidated tripeptide lysine derivatives (KKSM and KKSMB) was evaluated using various in vitro and animal-derived models of humoral and cell-mediated immune events in response to hepatitis B surface antigen (HBsAg). The results were compared with alum adjuvanted with HBsAg. Both these molecules were found to stimulate anti-HBsAg IgG and neutralizing (IgG1 and IgG2a) antibody titres in mice sera. The two molecules stimulated the proliferation of T-lymphocyte sub-sets (CD4/CD8) as well as the production of soluble mediators of Th1 (IL-2 and IFN-γ) and Th2 response (IL-4) in spleen cell culture supernatant. Furthermore, the two lipidated tripeptides enhanced the CD4, CD8, CD3 and CD19 cell populations as well as CD4/CD8 derived IL-2, IL-4, IFN-γ and TNF-α in whole blood of treated mice. There was found to be the significant enhancement in the release of IL-12, IFN-γ and nitrite content in macrophage supernatant. Moreover, the two lipidated tripeptides enhanced the population of CD80 and CD86 in spleen-derived macrophages and did not show any hemolytic effect on rabbit RBCs. Taken together, these results suggest that both these molecules are the potent enhancers of anti-HBsAg immune response via augmenting Th1/Th2 response in a dose dependent manner.
Collapse
Affiliation(s)
- Tabasum Sidiq
- Division of Pharmacology, Indian Institute of Integrative Medicine (CSIR), Jammu-180001, India
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Moyle PM, Toth I. Modern subunit vaccines: development, components, and research opportunities. ChemMedChem 2013; 8:360-76. [PMID: 23316023 DOI: 10.1002/cmdc.201200487] [Citation(s) in RCA: 310] [Impact Index Per Article: 28.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2012] [Revised: 12/08/2012] [Indexed: 12/11/2022]
Abstract
Traditional vaccines, based on the administration of killed or attenuated microorganisms, have proven to be among the most effective methods for disease prevention. Safety issues related to administering these complex mixtures, however, prevent their universal application. Through identification of the microbial components responsible for protective immunity, vaccine formulations can be simplified, enabling molecular-level vaccine characterization, improved safety profiles, prospects to develop new high-priority vaccines (e.g. for HIV, tuberculosis, and malaria), and the opportunity for extensive vaccine component optimization. This subunit approach, however, comes at the expense of decreased immunity, requiring the addition of immunostimulatory agents (adjuvants). As few adjuvants are currently used in licensed vaccines, adjuvant development represents an exciting area for medicinal chemists to play a role in the future of vaccine development. In addition, immune responses can be further customized though optimization of delivery systems, tuning the size of particulate vaccines, targeting specific cells of the immune system (e.g. dendritic cells), and adding components to aid vaccine efficacy in whole immunized populations (e.g. promiscuous T-helper epitopes). Herein we review the current state of the art and future direction in subunit vaccine development, with a focus on the described components and their potential to steer the immune response toward a desired response.
Collapse
Affiliation(s)
- Peter Michael Moyle
- School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, QLD 4072, Australia.
| | | |
Collapse
|
14
|
Apte SH, Groves PL, Skwarczynski M, Fujita Y, Chang C, Toth I, Doolan DL. Vaccination with lipid core peptides fails to induce epitope-specific T cell responses but confers non-specific protective immunity in a malaria model. PLoS One 2012; 7:e40928. [PMID: 22936972 PMCID: PMC3427299 DOI: 10.1371/journal.pone.0040928] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2012] [Accepted: 06/15/2012] [Indexed: 11/29/2022] Open
Abstract
Vaccines against many pathogens for which conventional approaches have failed remain an unmet public health priority. Synthetic peptide-based vaccines offer an attractive alternative to whole protein and whole organism vaccines, particularly for complex pathogens that cause chronic infection. Previously, we have reported a promising lipid core peptide (LCP) vaccine delivery system that incorporates the antigen, carrier, and adjuvant in a single molecular entity. LCP vaccines have been used to deliver several peptide subunit-based vaccine candidates and induced high titre functional antibodies and protected against Group A streptococcus in mice. Herein, we have evaluated whether LCP constructs incorporating defined CD4+ and/or CD8+ T cell epitopes could induce epitope-specific T cell responses and protect against pathogen challenge in a rodent malaria model. We show that LCP vaccines failed to induce an expansion of antigen-specific CD8+ T cells following primary immunization or by boosting. We further demonstrated that the LCP vaccines induced a non-specific type 2 polarized cytokine response, rather than an epitope-specific canonical CD8+ T cell type 1 response. Cytotoxic responses of unknown specificity were also induced. These non-specific responses were able to protect against parasite challenge. These data demonstrate that vaccination with lipid core peptides fails to induce canonical epitope-specific T cell responses, at least in our rodent model, but can nonetheless confer non-specific protective immunity against Plasmodium parasite challenge.
Collapse
Affiliation(s)
- Simon H. Apte
- Infectious Diseases Programme, Queensland Institute of Medical Research, Herston, Queensland, Australia
| | - Penny L. Groves
- Infectious Diseases Programme, Queensland Institute of Medical Research, Herston, Queensland, Australia
| | - Mariusz Skwarczynski
- School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Queensland, Australia
| | - Yoshio Fujita
- School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Queensland, Australia
| | - Chenghung Chang
- School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Queensland, Australia
| | - Istvan Toth
- School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Queensland, Australia
- School of Pharmacy, University of Queensland, St Lucia, Queensland, Australia
| | - Denise L. Doolan
- Infectious Diseases Programme, Queensland Institute of Medical Research, Herston, Queensland, Australia
- School of Medicine, University of Queensland, Herston, Queensland, Australia
- * E-mail:
| |
Collapse
|
15
|
Zaman M, Abdel-Aal ABM, Fujita Y, Phillipps KSM, Batzloff MR, Good MF, Toth I. Immunological evaluation of lipopeptide group A streptococcus (GAS) vaccine: structure-activity relationship. PLoS One 2012; 7:e30146. [PMID: 22253911 PMCID: PMC3257266 DOI: 10.1371/journal.pone.0030146] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2011] [Accepted: 12/12/2011] [Indexed: 11/18/2022] Open
Abstract
Streptococcus pyogenes (group A streptococcus, GAS) is a Gram-positive bacterial pathogen responsible for a wide variety of diseases. To date, GAS vaccine development has focused primarily on the M-protein. The M-protein is highly variable at the amino (N)-terminus (determining serotype) but is conserved at the carboxyl (C)-terminus. Previously a 29 amino acid peptide (named J14) from the conserved region of the M-protein was identified as a potential vaccine candidate. J14 was capable of eliciting protective antibodies that recognized many GAS serotypes when co-administered with immuno-stimulants. This minimal epitope however showed no immunogenicity when administered alone. In an attempt overcome this immunological non-responsiveness, we developed a self-adjuvanting vaccine candidate composed of three components: the B-cell epitope (J14), a universal helper T-cell epitope (P25) and a lipid moiety consisting of lipoamino acids (Laas) which target Toll-like receptor 2 (TLR2). Immunological evaluation in B10.BR (H-2k) mice demonstrated that the epitope attachment to the point of lipid moiety, and the length of the Laa alkyl chain have a profound effect on vaccine immunogenicity after intranasal administration. It was demonstrated that a vaccine featuring C-terminal lipid moiety containing alkyl chains of 16 carbons, with P25 located at the N-terminus, and J14 attached to the side chain of a central lysine residue was capable of inducing optimal antibody response. These findings have considerable relevance to the development of a broad spectrum J14-based GAS vaccine and in particular provided a rational basis for peptide vaccine design based on this self-adjuvanting lipopeptide technology.
Collapse
Affiliation(s)
- Mehfuz Zaman
- The University of Queensland, School of Chemistry and Molecular Biosciences (SCMB), St. Lucia, Queensland, Australia
| | - Abu-Baker M. Abdel-Aal
- The University of Queensland, School of Chemistry and Molecular Biosciences (SCMB), St. Lucia, Queensland, Australia
| | - Yoshio Fujita
- The University of Queensland, School of Chemistry and Molecular Biosciences (SCMB), St. Lucia, Queensland, Australia
| | - Karen S. M. Phillipps
- The University of Queensland, School of Chemistry and Molecular Biosciences (SCMB), St. Lucia, Queensland, Australia
| | - Michael R. Batzloff
- Institute for Glycomics, Griffith University, Gold Coast, Queensland, Australia
| | - Michael F. Good
- Institute for Glycomics, Griffith University, Gold Coast, Queensland, Australia
| | - Istvan Toth
- The University of Queensland, School of Chemistry and Molecular Biosciences (SCMB), St. Lucia, Queensland, Australia
- * E-mail:
| |
Collapse
|
16
|
Henningham A, Gillen CM, Walker MJ. Group a streptococcal vaccine candidates: potential for the development of a human vaccine. Curr Top Microbiol Immunol 2012; 368:207-42. [PMID: 23250780 DOI: 10.1007/82_2012_284] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Currently there is no commercial Group A Streptococcus (GAS; S. pyogenes) vaccine available. The development of safe GAS vaccines is challenging, researchers are confronted with obstacles such as the occurrence of many unique serotypes (there are greater than 150 M types), antigenic variation within the same serotype, large variations in the geographical distribution of serotypes, and the production of antibodies cross-reactive with human tissue which can lead to host auto-immune disease. Cell wall anchored, cell membrane associated, secreted and anchorless proteins have all been targeted as GAS vaccine candidates. As GAS is an exclusively human pathogen, the quest for an efficacious vaccine is further complicated by the lack of an animal model which mimics human disease and can be consistently and reproducibly colonized by multiple GAS strains.
Collapse
Affiliation(s)
- Anna Henningham
- School of Chemistry and Molecular Biosciences and Australian Infectious Disease Research Centre, University of Queensland, St Lucia, QLD 4072, Australia
| | | | | |
Collapse
|
17
|
Abstract
Disadvantages of classical vaccines, such as the risk of an autoimmune reaction, might be overcome by using a subunit vaccine containing the minimal microbial components necessary to stimulate appropriate immune responses. However, vaccines based on minimal epitopes suffer from poor immunogenicity and require the use of an additional immunostimulant (adjuvant). Only a few adjuvants have been permitted for use with vaccines intended for human administration. We have developed several vaccine candidates based on a lipid-core-peptide (LCP) system. This system has self-adjuvanting properties, and it can be used for the delivery of a variety of epitopes to produce vaccine candidates against a targeted disease. The LCP system is easily assembled by simple stepwise Boc solid-phase peptide synthesis.
Collapse
|
18
|
Simerska P, Moyle PM, Toth I. Modern lipid-, carbohydrate-, and peptide-based delivery systems for peptide, vaccine, and gene products. Med Res Rev 2009; 31:520-47. [DOI: 10.1002/med.20191] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
19
|
Novel strategies for controlling
Streptococcus pyogenes
infection and associated diseases: from potential peptide vaccines to antibody immunotherapy. Immunol Cell Biol 2009; 87:391-9. [DOI: 10.1038/icb.2009.29] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
20
|
Zhong W, Skwarczynski M, Toth I. Lipid Core Peptide System for Gene, Drug, and Vaccine Delivery. Aust J Chem 2009. [DOI: 10.1071/ch09149] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
A vast number of biologically active compounds await efficient delivery to become therapeutic agents. Lipidation has been demonstrated to be a convenient and useful approach to improve the stability and transport across biological membranes of potential drug molecules. The lipid core peptide (LCP) system has emerged as a promising lipidation tool because of its versatile features. This review discusses the progress in the development of the LCP system to improve cell permeability of nucleotides, physicochemical properties of potential drugs, and vaccine immunogenicity. Emphasis was put on the application of the LCP system to deliver antigens for the prevention of group A streptococcus infection, novel techniques of conjugation of target molecules to the LCP, and new alterations of the LCP system itself.
Collapse
|
21
|
|
22
|
Nomura Y, Abe Y, Ishida Y, Kobayashi H, Harabuchi Y. Promiscuous peptides on the nontypeable Haemophilus influenzae P6 outer membrane protein. J Clin Immunol 2008; 28:361-9. [PMID: 18379862 DOI: 10.1007/s10875-008-9189-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2007] [Accepted: 02/15/2008] [Indexed: 01/27/2023]
Abstract
INTRODUCTION P6 outer membrane protein is one of the candidates for a vaccine formulation against nontypeable Haemophilus influenzae (NTHi) infection. As otitis-prone children who have recurrent episodes of acute otitis media because of NTHi show an impaired immune response to P6, an innovative approach to vaccination is required to augment their immune response. RESULTS AND DISCUSSION We previously identified human HLA-DR9-restricted T cell epitope peptide and highly immunogenic analog peptides on P6 for peptide vaccine candidates. To develop a vaccine formulation effective in the general population, we identified promiscuous T cell epitope peptides (p41-55, p71-85) on P6. In addition to stimulating with potentially promiscuous peptides (p30-44, p45-59) selected using a computer algorithm, we established peptide-specific T cell lines which respond to P6. CONCLUSION Our present results indicate that these peptides would be candidates for a widely applicable peptide vaccine formulation.
Collapse
Affiliation(s)
- Yuka Nomura
- Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical College, Midorigaoka E2-1-1-1, Asahikawa, Hokkaido 078-8510, Japan
| | | | | | | | | |
Collapse
|
23
|
Simerska P, Abdel-Aal ABM, Fujita Y, Batzloff MR, Good MF, Toth I. Synthesis and in vivo studies of carbohydrate-based vaccines against group A Streptococcus. Biopolymers 2008; 90:611-6. [DOI: 10.1002/bip.20992] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
24
|
Simerska P, Abdel-Aal ABM, Fujita Y, Moyle PM, McGeary RP, Batzloff MR, Olive C, Good MF, Toth I. Development of a liposaccharide-based delivery system and its application to the design of group A streptococcal vaccines. J Med Chem 2008; 51:1447-52. [PMID: 18278857 DOI: 10.1021/jm701410p] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Group A streptococcus (GAS) is associated with many human diseases, ranging in severity from benign to life-threatening. A promising strategy for developing vaccines against GAS involves the use of carbohydrates as carriers for peptide antigens. This study describes the optimized synthesis of d-glucose and d-galactose derived carriers, bearing an adipate linker and four tert-butoxycarbonyl protected aminopropyl groups. Prophylactic GAS vaccine candidates were synthesized by conjugating multiple copies of a single GAS M protein derived peptide antigen (either J8 or J14) onto the carbohydrate carriers. These antigens contain peptide sequences, which are highly conserved and offer the potential to prevent infections caused by up to 70% of GAS strains. Lipophilic amino acids were also conjugated to the d-glucose anomeric carbon to produce a self-adjuvanting liposaccharide vaccine. High serum IgG antibody titers against each of the incorporated peptide epitopes were detected following subcutaneous immunization of B10.BR (H-2 (k)) mice with the liposaccharide vaccine candidates.
Collapse
Affiliation(s)
- Pavla Simerska
- School of Molecular and Microbial Sciences , The University of Queensland, St Lucia 4072, Queensland, Australia
| | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Abdel-Aal ABM, Batzloff MR, Fujita Y, Barozzi N, Faria A, Simerska P, Moyle PM, Good MF, Toth I. Structure–Activity Relationship of a Series of Synthetic Lipopeptide Self-Adjuvanting Group A Streptococcal Vaccine Candidates. J Med Chem 2007; 51:167-72. [DOI: 10.1021/jm701091d] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Abu-Baker M. Abdel-Aal
- School of Molecular and Microbial Sciences (SMMS), The University of Queensland, St. Lucia 4072, Queensland, Australia, and The Queensland Institute of Medical Research (QIMR), Herston 4029, Queensland, Australia
| | - Michael R. Batzloff
- School of Molecular and Microbial Sciences (SMMS), The University of Queensland, St. Lucia 4072, Queensland, Australia, and The Queensland Institute of Medical Research (QIMR), Herston 4029, Queensland, Australia
| | - Yoshio Fujita
- School of Molecular and Microbial Sciences (SMMS), The University of Queensland, St. Lucia 4072, Queensland, Australia, and The Queensland Institute of Medical Research (QIMR), Herston 4029, Queensland, Australia
| | - Nadia Barozzi
- School of Molecular and Microbial Sciences (SMMS), The University of Queensland, St. Lucia 4072, Queensland, Australia, and The Queensland Institute of Medical Research (QIMR), Herston 4029, Queensland, Australia
| | - Andres Faria
- School of Molecular and Microbial Sciences (SMMS), The University of Queensland, St. Lucia 4072, Queensland, Australia, and The Queensland Institute of Medical Research (QIMR), Herston 4029, Queensland, Australia
| | - Pavla Simerska
- School of Molecular and Microbial Sciences (SMMS), The University of Queensland, St. Lucia 4072, Queensland, Australia, and The Queensland Institute of Medical Research (QIMR), Herston 4029, Queensland, Australia
| | - Peter M. Moyle
- School of Molecular and Microbial Sciences (SMMS), The University of Queensland, St. Lucia 4072, Queensland, Australia, and The Queensland Institute of Medical Research (QIMR), Herston 4029, Queensland, Australia
| | - Michael F. Good
- School of Molecular and Microbial Sciences (SMMS), The University of Queensland, St. Lucia 4072, Queensland, Australia, and The Queensland Institute of Medical Research (QIMR), Herston 4029, Queensland, Australia
| | - Istvan Toth
- School of Molecular and Microbial Sciences (SMMS), The University of Queensland, St. Lucia 4072, Queensland, Australia, and The Queensland Institute of Medical Research (QIMR), Herston 4029, Queensland, Australia
| |
Collapse
|
26
|
Moyle PM, Hari Y, Huang N, Olive C, Good MF, Toth I. A technique for the synthesis of highly-pure, mono-epitopic, multi-valent lipid core peptide vaccines. Tetrahedron Lett 2007. [DOI: 10.1016/j.tetlet.2007.05.129] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
27
|
Batzloff MR, Pandey M, Olive C, Good MF. Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease. Immunol Res 2007; 35:233-48. [PMID: 17172649 DOI: 10.1385/ir:35:3:233] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/1999] [Revised: 11/30/1999] [Accepted: 11/30/1999] [Indexed: 11/11/2022]
Abstract
Rheumatic fever (RF) and rheumatic heart disease (RHD) are postinfectious complications of an infection (or repeated infection) with the Gram-positive bacterium, Streptococcus pyogenes (also known as group A streptococcus, GAS). RF and RHD are global problems and affect many indigenous populations of developed countries and many developing countries. However, RF and RHD are only part of a larger spectrum of diseases caused by this organism. The development of a vaccine against GAS has primarily targeted the abundant cell-surface protein called the M-protein. This review focuses on different M-protein-based-subunit vaccine approaches and the different delivery technologies used to administer these vaccine candidates in preclinical studies.
Collapse
Affiliation(s)
- Michael R Batzloff
- The Cooperative Research Centre for Vaccine Technology and the Australian Centre for International Tropical Health and Nutrition, The Queensland Institute of Medical Research, Post Office Royal Brisbane Hospital, Brisbane 4029, Australia
| | | | | | | |
Collapse
|
28
|
Ishida Y, Abe Y, Yanai M, Kobayashi H, Harabuchi Y. Identification of human T-cell epitopes and highly immunogenic analog peptides on the non-typeable Haemophilus influenzae P6 outer membrane protein. Clin Immunol 2006; 121:90-9. [PMID: 16901757 DOI: 10.1016/j.clim.2006.06.005] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2006] [Revised: 06/19/2006] [Accepted: 06/19/2006] [Indexed: 11/19/2022]
Abstract
P6 outer membrane protein is one of the candidates for a vaccine formulation against non-typeable Haemophilus influenzae (NTHi) infection. However, otitis-prone children who have recurrent episodes of acute otitis media due to NTHi fail to respond adequately to P6. An innovative approach to vaccination is therefore required to augment such children's immune response. To develop an effective peptide vaccine, we established P6-specific CD4(+) T-cell lines (TCLs) restricted by the human histocompatibility leukocyte antigen (HLA)-DR9 molecule, and revealed a human T-cell epitope on P6 and its core peptide sequence (p77-85; EYNIALGQR). Furthermore, we found that 3 analog peptides, E77D (the substitution of E at position 77 with D), N79G, and R85K, induced high proliferative responses as well as marked cytokine production when compared to the T-cell epitope peptide. These peptides may be candidates for a peptide vaccine formulation effective against NTHi infections, even in otitis-prone children.
Collapse
Affiliation(s)
- Yoshiya Ishida
- Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical College, Midorigaoka E2-1-1-1, Asahikawa, Hokkaido 078-8510, Japan
| | | | | | | | | |
Collapse
|
29
|
White K, Rades T, Kearns P, Toth I, Hook S. Immunogenicity of Liposomes Containing Lipid Core Peptides and the Adjuvant Quil A. Pharm Res 2006; 23:1473-81. [PMID: 16779706 DOI: 10.1007/s11095-006-0272-z] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2005] [Accepted: 02/21/2006] [Indexed: 10/24/2022]
Abstract
PURPOSE The purpose of this study was to investigate the immunogenicity of liposomes containing mannosylated lipid core peptide (manLCP) constructs, both in vitro and in vivo, with or without the addition of the immune stimulating adjuvant Quil A. METHODS Mouse bone marrow dendritic cells (BMDC) were cultured with liposome formulations for 48 h, and the resulting level of BMDC activation was determined by flow cytometry. BMDC pulsed with liposome formulations were incubated with 5,6-carboxyfluoroscein diacetate succinimidyl ester-labeled T cells for 72 h and the resulting T cell proliferation was determined by flow cytometry. To investigate the immunogenicity of formulations in vivo, groups of C57Bl/6J mice were immunized by subcutaneous injection, and the resulting antigen-specific cytotoxic and protective immune responses toward tumor challenge evaluated. RESULTS Despite being unable to demonstrate the activation of BMDC, BMDC pulsed with liposomes containing manLCP constructs were able to stimulate the proliferation of naïve T cells in vitro. However, in vivo only liposomes containing both manLCP and Quil A were able to stimulate a strong antigen-specific cytotoxic immune response. Liposomes containing manLCP and Quil A within the same particle were able to protect against the growth of tumor cells to a similar level as if the antigen was administered in alum with CD4 help. CONCLUSION ManLCPs administered in liposomes are able to stimulate strong cytotoxic and protective immune responses if Quil A is also incorporated as an adjuvant.
Collapse
MESH Headings
- Adjuvants, Immunologic/administration & dosage
- Animals
- Antigens, CD/immunology
- Antigens, Differentiation, Myelomonocytic/immunology
- Bone Marrow Cells/immunology
- Cancer Vaccines/administration & dosage
- Cancer Vaccines/chemistry
- Cancer Vaccines/immunology
- Cell Proliferation
- Cells, Cultured
- Chemistry, Pharmaceutical
- Dendritic Cells/immunology
- Epitopes, T-Lymphocyte/administration & dosage
- Epitopes, T-Lymphocyte/chemistry
- Epitopes, T-Lymphocyte/immunology
- Injections, Subcutaneous
- Lipoproteins/administration & dosage
- Lipoproteins/chemical synthesis
- Lipoproteins/immunology
- Liposomes/chemistry
- Mannose/administration & dosage
- Mannose/chemistry
- Mannose/immunology
- Mice
- Mice, Inbred C57BL
- Neoplasms, Experimental/immunology
- Neoplasms, Experimental/prevention & control
- Peptide Fragments/administration & dosage
- Peptide Fragments/chemistry
- Peptide Fragments/immunology
- Phospholipids/administration & dosage
- Phospholipids/chemistry
- Phospholipids/immunology
- Quillaja Saponins
- Saponins/administration & dosage
- Saponins/immunology
- T-Lymphocytes, Cytotoxic/immunology
Collapse
Affiliation(s)
- Karen White
- School of Pharmacy, University of Otago, PO Box 913, Dunedin, New Zealand
| | | | | | | | | |
Collapse
|
30
|
Raman S, Machaidze G, Lustig A, Aebi U, Burkhard P. Structure-based design of peptides that self-assemble into regular polyhedral nanoparticles. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2006; 2:95-102. [PMID: 17292121 DOI: 10.1016/j.nano.2006.04.007] [Citation(s) in RCA: 133] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/22/2006] [Accepted: 04/07/2006] [Indexed: 11/29/2022]
Abstract
Artificial particulate systems such as polymeric beads and liposomes are being applied in drug delivery, drug targeting, antigen display, vaccination, and other technologies. Here we used computer modeling to design a novel type of nanoparticles composed of peptides as building blocks. We verified the computer models via solid-phase peptide synthesis and biophysical analyses. We describe the structure-based design of a novel type of nanoparticles with regular polyhedral symmetry and a diameter of about 16 nm, which self-assembles from single polypeptide chains. Each peptide chain is composed of two coiled coil oligomerization domains with different oligomerization states joined by a short linker segment. In aqueous solution the peptides form nanoparticles of about 16 nm diameter. Such peptide nanoparticles are ideally suited for medical applications such as drug targeting and drug delivery systems, such as imaging devices, or they may be used for repetitive antigen display.
Collapse
Affiliation(s)
- Senthilkumar Raman
- M.E. Müller Institute for Structural Biology, Biozentrum, University of Basel, Basel, Switzerland
| | | | | | | | | |
Collapse
|
31
|
White K, Kearns P, Toth I, Hook S. Increased adjuvant activity of minimal CD8 T cell peptides incorporated into lipid‐core‐peptides. Immunol Cell Biol 2004; 82:517-22. [PMID: 15479437 DOI: 10.1111/j.0818-9641.2004.01269.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
A problem facing the use of subunit peptide and protein vaccines is their inability to stimulate protective immune responses. Many different approaches have been utilized to overcome this inefficient immune activation. The approach we have taken is to modify the vaccine antigen so that it now has adjuvant properties. To do this, multiple copies of minimal CD8 T cell epitopes were attached to a poly lysine lipid core. These constructs are known as lipid-core-peptides (LCP). The research presented here examines the adjuvant activity of LCP. Using mouse models, we were able to show that LCP were indeed able to activate antigen-presenting cells in vitro and to activate cytotoxic T-cell responses in vivo. More importantly, LCP were able to stimulate the development of a protective antitumour immune response.
Collapse
Affiliation(s)
- Karen White
- School of Pharmacy, University of Otago, Dunedin, New Zealand
| | | | | | | |
Collapse
|
32
|
Horváth A, Olive C, Karpati L, Sun HK, Good M, Toth I. Toward the development of a synthetic group a streptococcal vaccine of high purity and broad protective coverage. J Med Chem 2004; 47:4100-4. [PMID: 15267249 DOI: 10.1021/jm040041w] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Using native chemical ligation, we synthesized a group A streptococcal (GAS) vaccine that contained three different GAS M protein peptide epitopes in a chemically well-characterized construct in high purity. Two of the peptide epitopes represented variable amino terminal serotype determinants, and the third represented a carboxyl terminal conserved region determinant of the GAS M protein. We also synthesized a lipid core peptide (LCP) construct containing the same three peptides. Upon immunization of mice, the non-LCP construct only elicited antibody responses to all three epitopes with the use of adjuvant. The LCP construct, however, elicited excellent antibody responses to all three epitopes without the need for any additional adjuvant or carrier. We have synthesized the LCP synthetic vaccine system with good reproducibility.
Collapse
Affiliation(s)
- Anikó Horváth
- School of Pharmacy and School of Molecular and Microbial Sciences, The University of Queensland, Brisbane 4072, Australia
| | | | | | | | | | | |
Collapse
|
33
|
Development of lipid-core-peptide (LCP) based vaccines for the prevention of group A streptococcal (GAS) infection. Int J Pept Res Ther 2003. [DOI: 10.1007/s10989-004-2431-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
34
|
Development of lipid-core-peptide (LCP) based vaccines for the prevention of group A streptococcal (GAS) infection. ACTA ACUST UNITED AC 2003. [DOI: 10.1007/bf02442594] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|